1-4 of 4
Veronica Asnaghi
Close
Sort by
Journal Articles

Emapalumab, a Fully Human Anti-Interferon Gamma Monoclonal Antibody, in Pediatric Patients with Primary Hemophagocytic Lymphohistiocytosis: Long-Term Follow-up of a Phase 2/3 Study

Michael B. Jordan, Carl Allen, Anupama Rao, Carmelo Rizzari, Simone Cesaro, Maria Caterina Putti, Julian Sevilla, Cristina de Min, Maria Ballabio, Veronica Asnaghi, Anna Stoltenberg, Radmila Kanceva, Franco Locatelli
Journal: Blood
Blood (2023) 142 (Supplement 1): 1174.
https://doi.org/10.1182/blood-2023-179362
Published: 2023
Journal Articles

Trials in Progress: A Two-Cohort, Open-Label, Single-Arm Study of Emapalumab, an Anti-Interferon Gamma (IFNγ) Monoclonal Antibody, in Patients with Macrophage Activation Syndrome (MAS) in Rheumatic Diseases

Alexei A Grom, Jeanette Bachir, Veronica Asnaghi, Fabrizio De Benedetti
Journal: Blood
Blood (2021) 138 (Supplement 1): 4195.
https://doi.org/10.1182/blood-2021-146770
Published: 2021
Journal Articles

Macrophage Activation Syndrome (MAS) in Systemic Juvenile Idiopathic Arthritis (sJIA): Treatment with Emapalumab, an Anti-Interferon Gamma (IFNγ) Monoclonal Antibody

Fabrizio De Benedetti, Alexei A Grom, Paul Brogan, Claudia Bracaglia, Manuela Pardeo, Giulia Marucci, Despina Eleftheriou, Charalampia Papadopoulou, Pierre Quartier, Jordi Antón, Rikke Frederiksen, Veronica Asnaghi, Maria Ballabio, Cristina de Min
Journal: Blood
Blood (2021) 138 (Supplement 1): 2058.
https://doi.org/10.1182/blood-2021-147596
Published: 2021
Journal Articles

An Adaptive Design Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Emapalumab in Adult Patients with Non-Primary Hemophagocytic Lymphohistiocytosis

Veronica Asnaghi, MD, Maria Ballabio, MD, Philippe Jacqmin, Kathy de Graaf, Cristina De Min, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2333.
https://doi.org/10.1182/blood-2019-123995
Published: 2019